Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Boston Therapeutics Inc reports topline U.S.-based phase IIb study results of BTI-320 in patients with type 2 diabetes
Boston Therapeutics Inc reports topline U.S.-based phase IIb study results of BTI-320 in patients with type 2 diabetes
Boston Therapeutics Inc reports topline U.S.-based phase IIb study results of BTI-320 in patients with type 2 diabetes
Submitted by
admin
on October 9, 2014 - 10:54am
Source:
Reuters
News Tags:
Boston Therapeutics
type 2 diabetes
BTI-320
Headline:
Boston Therapeutics Inc reports topline U.S.-based phase IIb study results of BTI-320 in patients with type 2 diabetes
Do Not Allow Advertisers to Use My Personal information
